AstraZeneca

EsoBiotec is a Belgian biotechnology company dedicated to the discovery and development of novel cancer therapies. The firm focuses on empowering the human body to combat cancer through in vivo cell engineering. By creating innovative immunotherapies, EsoBiotec aims to provide cost-effective drugs and therapeutics that enhance accessibility, ensuring that patients can receive essential cancer treatments at lower costs.

FibroGen China is committed to providing access to revolutionary medical treatment for patients.

Syneron was founded by Sinovation Ventures and is dedicated to using artificial intelligence and biotechnology to address two significant global challenges: the efficient development of novel biological therapies and the low-carbon manufacture of biochemicals.

Huma is a global health technology company that specializes in creating a modular platform for digital 'hospitals at home' across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting information from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time insights. The company focuses on advancing connected care for patients and accelerating research and therapy development. It collaborates with leading healthcare institutions to assess and improve health outcomes, empowering healthcare professionals to utilize data effectively for better patient care.

Nucleus RadioPharma is a company focused on enhancing access to innovative radiopharmaceuticals for cancer patients. It is dedicated to developing technologies that modernize the clinical development, manufacturing, and supply chain processes associated with these therapies. By specializing in novel treatments and technologies, Nucleus RadioPharma aims to improve the diagnosis and treatment of various cancers, ensuring that healthcare professionals can effectively utilize these advanced medical solutions.

SixPeaks Bio focuses on developing innovative therapies aimed at promoting healthy weight loss for individuals struggling with obesity. The company is working on a pipeline of medicines that utilize dual-specific antibodies to target activin type IIA and B receptors. This approach aims to help patients achieve weight loss while preserving skeletal muscle mass, addressing a common concern associated with traditional weight-loss methods that often lead to muscle loss alongside fat reduction. Through its research and development efforts, SixPeaks Bio seeks to provide effective solutions for sustainable weight management and improved health outcomes.

SixPeaks Bio focuses on developing innovative therapies aimed at promoting healthy weight loss for individuals struggling with obesity. The company is working on a pipeline of medicines that utilize dual-specific antibodies to target activin type IIA and B receptors. This approach aims to help patients achieve weight loss while preserving skeletal muscle mass, addressing a common concern associated with traditional weight-loss methods that often lead to muscle loss alongside fat reduction. Through its research and development efforts, SixPeaks Bio seeks to provide effective solutions for sustainable weight management and improved health outcomes.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Nabla Bio operates an autoreverse platform that facilitates the rapid discovery of novel protein variants with unique properties. By leveraging insights gained from billions of natural proteins, the company engineers these enhanced proteins for both medical and industrial applications. Through extensive experimentation, Nabla Bio develops new medicines and improves nutritional products, allowing clients to conduct complex measurements of protein function and implement innovative solutions in various fields.

Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company's key programs include AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining sustained calcium levels in the blood, and AZP-3404, a novel peptide designed to improve fat and glucose metabolism. By addressing severe insulin resistance and other critical metabolic conditions, Amolyt Pharma aims to provide effective treatment options for patients facing these rare disorders.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Cellectis S.A. is a clinical-stage biotechnological company based in Paris, France, focused on developing innovative immuno-oncology therapies using gene-edited T-cells. The company specializes in allogeneic Chimeric Antigen Receptor T-cell (CAR-T) products, with a portfolio that includes several product candidates targeting various hematologic malignancies. Notable candidates include UCART19, aimed at treating CD19-expressing hematologic cancers such as acute lymphoblastic leukemia; UCART123 for acute myeloid leukemia; and UCARTCS1 and ALLO-715 for multiple myeloma. In addition to its therapeutic efforts, Cellectis also produces high oleic soybean oil and other soybean products, as well as fiber wheat. The company collaborates with various strategic partners, including Allogene Therapeutics and The University of Texas M.D. Anderson Cancer Center. Founded in 1999, Cellectis continues to advance its mission of eradicating cancer through cutting-edge gene-editing technologies.

Cullgen Inc. is a biopharmaceutical company based in San Diego, California, founded in 2018. The company specializes in the development of innovative small molecule therapeutics aimed at treating diseases that currently lack effective therapeutic options, including cancer, inflammatory, and autoimmune diseases. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins, even those previously deemed undruggable. This approach enables the creation of first-in-class new chemical entities, providing scientists with novel methodologies for drug discovery and potentially transforming treatment paradigms for difficult-to-treat conditions.

Promise Bio is focused on pioneering precision medicine by utilizing epiproteomic analysis to understand autoimmune diseases. The company employs a cloud-based AI platform to perform comprehensive analyses of standard mass-spectrometry data, revealing insights into protein modifications that affect disease mechanisms.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.

GenAssist Therapeutics is a biotechnology company founded in July 2020 that specializes in developing gene therapy drugs using advanced base editing technology. The company focuses on addressing genetic diseases, particularly neuromuscular disorders such as Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA), for which effective treatments are currently lacking. By employing Targeted AID-based Mutagenesis (TAM) technology, GenAssist aims to precisely repair disease-causing genes in situ, offering the potential for permanent cures. The company possesses global intellectual property rights for its innovative approach, reflecting its commitment to advancing gene editing therapies across a range of genetic conditions.

Neogene Therapeutics, Inc. is a biotechnology company based in New York, founded in 2018, that focuses on developing T cell therapies for cancer treatment. The company specializes in creating personalized engineered T cells that target neo-antigens, which are mutated proteins present in cancer cells due to DNA mutations. By leveraging advanced technologies, Neogene isolates T cell receptor (TCR) genes specific to these neo-antigens from tumor biopsies routinely collected from patients. This process utilizes high-sensitivity DNA sequencing and genetic screening to identify TCRs that can effectively recognize and attack cancer cells. Neogene's innovative approach aims to enhance the precision and efficacy of cancer therapies, offering improved treatment options for patients facing a broad spectrum of cancers.

Rgenta Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of RNA-targeting medicines with a primary focus on oncology and neurological disorders. Founded in 2018, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This platform enables the design of small-molecule compounds that modulate interactions among the spliceosome, regulatory proteins, and RNAs. By unlocking the therapeutic potential of previously undruggable targets, Rgenta aims to create oral, small-molecule therapies that address critical needs in human disease treatment, particularly in the realm of cancer.

ZSHK Lab is a company located in Wan Chai, Hong Kong Island, Hong Kong.

Yunjian is a new generation of metabolomics- and protein-based marker-finding technologies. has developed a distinctive analytic platform based on mass spectrometry proteomics and big data, driven by medical theories that greatly reduce the time required by conventional methods to find disease markers. has a wealth of experience in big data illness models, medication development, disease biomarker identification, clinical translation and diagnostics, and data security.

Doctor.One operates a virtual clinic designed to empower doctors to establish subscription-based private practices. The platform facilitates direct communication between doctors and patients, allowing physicians to manage their practices through features such as asynchronous messaging, video calls, and prescription issuance without compromising personal contact information. By offering a streamlined approach to healthcare, Doctor.One aims to enhance the doctor-patient relationship and provide patients with direct access to their healthcare providers. The company's innovative model seeks to restore trust and personalization in medical care, making healthcare more accessible and efficient.

TeneoTwo is a biotechnology firm that develops potential new medicine for B-cell haematologic malignancies, including diffuse large B-cell lymphoma and follicular lymphoma.

Axbio Inc. is a biotechnology company based in Shenzhen, China, specializing in genetic sequencing technology and diagnostic solutions. Founded in 2016, the company develops a variety of products, including genome extraction kits for stool, blood, saliva, and bacteria. Axbio also provides advanced sequencing systems, disposable biochips, and reagents. The company is focused on creating high-throughput molecular diagnostics through its novel microfluidic Bio-CMOS platform, which supports both low-cost handheld devices for bedside diagnostics and fully automated laboratory instruments. This technology enables applications such as early cancer screening, rapid pathogen detection, and drug development. Currently, Axbio operates in stealth mode as it continues to innovate within the field.

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

Huma is a global health technology company that specializes in creating a modular platform for digital 'hospitals at home' across various disease areas. The platform integrates predictive algorithms, digital biomarkers, and real-world data to enhance proactive and predictive healthcare. By connecting information from hospital databases, patient wearables, and mobile devices, Huma provides healthcare providers with real-time insights. The company focuses on advancing connected care for patients and accelerating research and therapy development. It collaborates with leading healthcare institutions to assess and improve health outcomes, empowering healthcare professionals to utilize data effectively for better patient care.

Creativity (Beijing) Medical Technology Development Co., Ltd. is a leading minimally invasive interventional delivery system product full solution provider. Committed to cooperating with top experts at home and abroad in the field of minimally invasive intervention, and cooperating with internationally renowned raw material manufacturers to jointly develop, produce and sell leading products. Provide doctors with differentiated diagnosis and treatment tools, relieve patients' pain and reduce medical burden.

Caelum Biosciences is a clinical-stage biotechnology company focused on developing treatments for rare and life-threatening diseases. Its primary asset, CAEL-101, is a novel antibody licensed from Columbia University that targets amyloid light chain (AL) amyloidosis, a serious condition that can result in organ failure. Clinical data have indicated that CAEL-101 may be a safe and well-tolerated therapy that promotes the resolution of amyloid deposits, which can improve patients' health outcomes. Notably, the treatment has shown a correlation between reduced levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and enhanced cardiac function in patients with cardiac AL amyloidosis. CAEL-101 has received Orphan Drug Designation from the U.S. Food and Drug Administration, recognizing its potential to address this rare disease. In 2019, Caelum entered into a collaboration agreement with Alexion Pharmaceuticals to further develop CAEL-101, which included a significant financial commitment from Alexion to support the project.

Cellular Biomedicine Group, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer and stem cell therapies for degenerative diseases, particularly in Greater China. The company utilizes proprietary cell-based technologies to create treatments, including various forms of CAR-T therapies targeting different cancer types, such as CD20 for anti-tumor activities, CD22 for B cell malignancies, and therapies aimed at refractory multiple myeloma. Additionally, the company develops NKG2D CAR therapies and treatments for hepatocellular carcinoma, alongside knee osteoarthritis therapies currently undergoing clinical trials. Beyond its therapeutic development, Cellular Biomedicine Group is involved in biopharmaceutical activities encompassing research and development, technical support, and the manufacturing of pharmaceutical products and medical devices. It also operates under a collaboration agreement with Novartis Pharma AG to manufacture and supply the CAR-T cell therapy Kymriah in China. Established in 2001, the company integrates over thirty years of research and clinical experience in cellular medicine, drawing on expertise from collaborations among scientists and medical professionals across the United States, England, and China.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

OnDosis is a company focused on transforming medication delivery through its proprietary technology, which allows for flexible and individualized dosing of oral medicines formulated as micro units. The company aims to enhance disease management, support patient adherence, and improve convenience for individuals with conditions such as ADHD, pain management, and organ transplant immunosuppression. By offering improved dosing options, OnDosis seeks to address significant healthcare burdens and ultimately enhance patient outcomes. Founded in 2017 and headquartered in Gothenburg, Sweden, OnDosis emerged from research initiated at AstraZeneca and is supported by strategic partnerships in formulation, device development, regulatory affairs, and business development. The company's innovative dosage manager integrates digital technologies with conventional drug treatments, positioning it to make a meaningful impact in personalized medicine.

ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company is advancing its lead product candidates, including ADCT-402, which is undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, currently in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. In addition to these, ADC Therapeutics is developing other clinical-stage candidates like ADCT-601 and ADCT-602, as well as several preclinical candidates. The company utilizes advanced pyrrolobenzodiazepine (PBD) dimer technology, which enhances the potency and specificity of its ADCs compared to earlier generations. ADC Therapeutics has established a collaboration and licensing agreement with Genmab A/S to further its research and development efforts. The company was founded in 2011 and continues to focus on innovative cancer therapies.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company is engaged in creating first-in-class immunotherapy drug candidates, leveraging its proprietary platform to harness the innate immune system. Key products in its pipeline include Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody also in Phase II for cutaneous T-cell lymphoma. Additionally, the pipeline features various candidates at different stages, including IPH5201 and IPH5301, which target immunosuppressive pathways. Innate Pharma has established licensing and collaboration agreements with major pharmaceutical companies, enhancing its research and development capabilities. Founded in 1999, the company operates internationally, contributing to the advancement of cancer treatment through innovative therapeutic approaches.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Viela Bio, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, focused on the research and development of innovative treatments for severe inflammation and autoimmune diseases. The company's lead product candidate, inebilizumab, is a humanized monoclonal antibody targeting CD19, designed for conditions such as neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. In addition to inebilizumab, Viela Bio is developing VIB4920, aimed at preventing kidney transplant rejection and treating Sjögren's syndrome, and VIB7734, which targets cutaneous lupus erythematosus. The company has formed a strategic partnership with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases across several countries in Asia. Founded in 2017, Viela Bio is committed to addressing critical pathways underlying autoimmune diseases to improve patient outcomes.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company that focuses on the development of oral delivery technologies for large drug molecules, such as peptides, proteins, and antibodies. The company has created the RaniPill capsule, a proprietary and patented platform designed to administer biologics orally, offering a convenient alternative to traditional subcutaneous or intravenous injections. This capsule is engineered to deliver precise therapeutic doses upon reaching the small intestine. Rani Therapeutics is advancing various treatments, including TNFa inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, their portfolio includes therapies for multiple sclerosis, type II diabetes, and various inflammatory diseases. Founded in 2012 and based in San Jose, California, Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety and effectiveness of its technologies, building a robust intellectual property portfolio in the process.

ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company is advancing its lead product candidates, including ADCT-402, which is undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, currently in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. In addition to these, ADC Therapeutics is developing other clinical-stage candidates like ADCT-601 and ADCT-602, as well as several preclinical candidates. The company utilizes advanced pyrrolobenzodiazepine (PBD) dimer technology, which enhances the potency and specificity of its ADCs compared to earlier generations. ADC Therapeutics has established a collaboration and licensing agreement with Genmab A/S to further its research and development efforts. The company was founded in 2011 and continues to focus on innovative cancer therapies.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company that focuses on the development of oral delivery technologies for large drug molecules, such as peptides, proteins, and antibodies. The company has created the RaniPill capsule, a proprietary and patented platform designed to administer biologics orally, offering a convenient alternative to traditional subcutaneous or intravenous injections. This capsule is engineered to deliver precise therapeutic doses upon reaching the small intestine. Rani Therapeutics is advancing various treatments, including TNFa inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, their portfolio includes therapies for multiple sclerosis, type II diabetes, and various inflammatory diseases. Founded in 2012 and based in San Jose, California, Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety and effectiveness of its technologies, building a robust intellectual property portfolio in the process.

Ethris GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative therapeutic solutions for diseases with unmet medical needs. The company has a focus on transcript therapeutics, particularly through its SNIM RNA platform, which offers a novel approach to treating various conditions by enabling the production of therapeutic proteins within the patient’s body. This platform presents an alternative to traditional recombinant protein and gene therapies, addressing a range of diseases, including rare and genetically predetermined conditions. Ethris also develops Magnetovax, a personalized tumor vaccine platform that utilizes magnetic fields for localized activation in tumors. The company has established strategic research collaborations with major pharmaceutical firms, enhancing its capabilities in regenerative medicine and therapeutic development. Founded in 2009, Ethris continues to advance its technologies to meet diverse medical needs.

ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company is advancing its lead product candidates, including ADCT-402, which is undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, currently in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. In addition to these, ADC Therapeutics is developing other clinical-stage candidates like ADCT-601 and ADCT-602, as well as several preclinical candidates. The company utilizes advanced pyrrolobenzodiazepine (PBD) dimer technology, which enhances the potency and specificity of its ADCs compared to earlier generations. ADC Therapeutics has established a collaboration and licensing agreement with Genmab A/S to further its research and development efforts. The company was founded in 2011 and continues to focus on innovative cancer therapies.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

FibroGen, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing therapeutics to address significant unmet medical needs. The company is advancing Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylases, which is in Phase III clinical development for treating anemia in chronic kidney disease in the United States and Europe, and in Phase II/III development for anemia associated with myelodysplastic syndromes in China. Additionally, FibroGen is developing Pamrevlumab, a human monoclonal antibody that targets connective tissue growth factor, currently in Phase III trials for idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, along with a Phase II trial for Duchenne muscular dystrophy. The company has established collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Founded in 1993 and headquartered in San Francisco, California, FibroGen generates most of its revenue through these collaborative partnerships.

Takeda defined four therapeutic areas of focus: Gastroenterology, Oncology, Central Nervous System, and Cardiovascular and Metabolic.

Rani Therapeutics, LLC is a clinical-stage biotherapeutics company that focuses on the development of oral delivery technologies for large drug molecules, such as peptides, proteins, and antibodies. The company has created the RaniPill capsule, a proprietary and patented platform designed to administer biologics orally, offering a convenient alternative to traditional subcutaneous or intravenous injections. This capsule is engineered to deliver precise therapeutic doses upon reaching the small intestine. Rani Therapeutics is advancing various treatments, including TNFa inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, their portfolio includes therapies for multiple sclerosis, type II diabetes, and various inflammatory diseases. Founded in 2012 and based in San Jose, California, Rani Therapeutics has conducted several preclinical and clinical studies to assess the safety and effectiveness of its technologies, building a robust intellectual property portfolio in the process.

Acerta Pharma is focused on the development of covalent binding technology solutions to create therapies for cancer. Acerta Pharma was acquired by AstraZeneca in February 2016. Acerta Pharma was founded in 2013 and is based in San Carlos, California.

ZS Pharma, Inc. is a biopharmaceutical company based in Coppell, Texas, focused on developing non-absorbed drugs for renal, cardiovascular, liver, and metabolic diseases. Established in 2008, the company specializes in highly selective ion-trap therapies, particularly its lead candidate, ZS-9. This innovative treatment employs proprietary zirconium silicate technology to create ion traps that can effectively reduce excess potassium levels in patients suffering from hyperkalemia, a serious condition often associated with chronic kidney disease, hypertension, diabetes, and heart failure. ZS-9 is currently undergoing late-stage clinical trials to evaluate its efficacy and safety. As of December 2015, ZS Pharma operates as a subsidiary of Zeneca, Inc.

ADC Therapeutics SA is a clinical-stage biotechnology company based in Epalinges, Switzerland, specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company is advancing its lead product candidates, including ADCT-402, which is undergoing a Phase II clinical trial for relapsed or refractory diffuse large B-cell lymphoma, and ADCT-301, currently in a pivotal Phase II trial for relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. In addition to these, ADC Therapeutics is developing other clinical-stage candidates like ADCT-601 and ADCT-602, as well as several preclinical candidates. The company utilizes advanced pyrrolobenzodiazepine (PBD) dimer technology, which enhances the potency and specificity of its ADCs compared to earlier generations. ADC Therapeutics has established a collaboration and licensing agreement with Genmab A/S to further its research and development efforts. The company was founded in 2011 and continues to focus on innovative cancer therapies.

PhaseBio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for endocrine and metabolic disorders, as well as cardiovascular diseases. The company leverages its proprietary elastin-like polypeptides (ELPs) technology to enhance the stability, bioavailability, and efficacy of proteins and peptides. Its lead candidate, PB1023, is in a phase 2b clinical trial for managing hyperglycemia in type 2 diabetes, with potential applications in obesity. Additionally, PhaseBio is advancing Vasomera, a candidate in phase 1 trials aimed at treating pulmonary arterial hypertension and heart failure. The company is also exploring PB2452, a novel reversal agent for the antiplatelet drug ticagrelor, and PB1046 for pulmonary arterial hypertension. With a commitment to addressing unmet medical needs, PhaseBio is headquartered in Malvern, Pennsylvania.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

MdBio Foundation, Inc. has been providing innovative and effective bioscience education for middle and high school students since 1997. The non-profit, (501 c 3) organization is dedicated to providing bioscience awareness, education, and workforce development in the state of Maryland and beyond. The Foundation accomplishes this through a diverse set of programs, including their flagship program, MdBioLab, summer programs, and their leading-edge game-based learning platform, MdBioSphere. MdBio Foundation leverages its established, trusted relationships with private industry and school systems to create authentic, STEM-based career experiences on their mobile laboratory, MdBioLab, and through their youth camp, the Young Science Explorers Program (YSEP). These experiences provide a unique opportunity for students to observe first hand the types of careers they could pursue in STEM-related fields. Students and teachers who participate in MdBioLab and YSEP have increased access to information about bioscience industry products, research, and related careers through problem-based laboratory experiences that are aligned with local, state and, national curriculum standards. Commitment to Excellence: Since its inception, The MdBio Foundation has contributed more than $3.5M of their resources to these programs and will continue to invest more than $500K each year. The Foundation’s staff consists of talented and experienced educators and scientists who share a common goal of improving science education and creating a more accessible, educational experience.

Almirall is an international pharmaceutical company based in Barcelona, Spain, focused on innovation and dedicated to improving health and wellbeing. The company engages in the research, development, manufacture, and marketing of medicinal products across various therapeutic areas, including dermatology, respiratory, gastrointestinal, and central nervous system disorders. Almirall operates through multiple segments, including sales through its own network, licensed products, and research and development initiatives. Its medical dermatology business in Europe is a primary driver of its operations, while the company also extends its presence to the Americas, Asia, Africa, and Oceania through subsidiaries.

The Ashland-Boyd County Health Department, situated in the Appalachian highlands of eastern Kentucky, is dedicated to enhancing the quality of life for residents in Boyd County. The department focuses on disease prevention, health promotion, environmental safety, and public health preparedness. Its services include public health awareness campaigns aimed at educating the community about various health issues. The department specifically supports vulnerable populations, such as pregnant women, postpartum women, and infants, by providing nutrition education, breastfeeding information, and access to nutritious foods and healthcare services. Through these efforts, the Ashland-Boyd County Health Department plays a crucial role in fostering a healthier community.

UnityPoint Health is a prominent nonprofit health system in the United States, established in 1993. It operates an integrated network that includes over 280 physician clinics, 30 hospitals, and home care services across eight regions in Iowa and Illinois. The organization prioritizes effective communication among its physician-led teams to ensure patients receive appropriate care in clinics, hospitals, or at home. Annually, UnityPoint Health facilitates more than 4 million patient visits, delivering a comprehensive range of coordinated healthcare services to individuals and families. With annual revenues of $2.7 billion, it ranks as the 13th largest nonprofit health system in the nation and the fourth largest nondenominational health system.

Elkhorn Logan Valley Public Health Department was created in 2002 to serve the citizens and communities of Burt, Cuming, Madison and Stanton counties. Located in Wisner, Nebraska, with a satellite office in Norfolk, the department focuses on healthy lifestyle management and disease prevention with over 20 programs initiated to maximize wellness and safety.

North Georgia Healthcare Center is a non-profit health care center in Ringgold, Georgia. NGHCC is federally funded by the U.S.D.A. Direct Loan Program funds. The organization will seek sponsorship through private corporations, community, and grants and it will accept Private Insurance, Medicare, Medicaid. NGHCC will offer medical services to North Georgia and surrounding areas seven days a week with extended hours.

Established in 1996, Catherine’s Health Center is a 501(c)(3) safety net medical clinic, serving more than 6,000 patients annually. Using a small core of paid staff and many dedicated volunteers, Catherine’s mission is to provide free or low-cost medical services to low-income, uninsured and underinsured residents of Kent Count.Catherine’s Health Center is a non-profit community-based health facility dedicated to serving low-income, uninsured residents of the northeast sections of Grand Rapids, Michigan, primarily those who live in the Creston and Belknap neighborhoods. Supporting the center’s activities are a governing board and group of volunteers working to make health care available to those in need.

Allegiance Health is a community-owned, locally-governed health system in Jackson, Michigan. We combine hospital-based care with a full range of services for all members of our community. Allegiance is a leader in forming community partnerships which innovatively address wellness and preventative needs. We are proudly entering our 10th decade of serving the people of south central Michigan with local, high-quality care.Comprised of more than 40 different facilities, Allegiance reaches the residents of Jackson, Hillsdale, Lenawee, Ingham, Calhoun and Washtenaw counties and beyond. Wherever we are in the region, our mission remains constant. We lead our community to better health and well-being at every stage of life. Our vision is to create Michigan’s healthiest community through exceptional health care and inspiring a passion for wellness.

Matthew Walker Comprehensive Health Center, Inc. provides healthcare and health education services. It provides pediatric care, family and internal medicine, general dentistry, ophthalmology, geriatrics, obstetrics and gynecology, nutrition, mental health, pharmacy, radiology, and diagnostic laboratory testing and screening services. The company was founded in 1968 and is based in Nashville, Tennessee.

The Health Wagon is a nonprofit organization providing mobile health services to the medically underserved in southwest Virginia. The Health Wagon’s mission is to provide compassionate, quality healthcare to the medically underserved in the mountains of Appalachia. The Health Wagon visits 10 sites in six counties – Buchanan, Dickenson, Lee, Russell, Scott, and Wise counties – to serve a severely medically underserved population. The Health Wagon currently has two mobile health units and two stationary clinics servicing southwest Virginia.

Whittier Street Health Center (WSHC) is a comprehensive, innovative and high quality health care and wellness center championing equitable access to high quality, cost-effective health care for diverse populations. WSHC is accredited by The Joint Commission (TJC), certified by the NCQA as a golden level (highest ranking) patient centered medical home and licensed by the Massachusetts Department of Public Health (DPH). The vision of the Whittier Street Health Center is to serve as the premiere health center for Boston residents and the mission is to provide high quality, reliable and accessible primary care and support services to promote wellness and eliminate health and social disparities. Located in the Roxbury neighborhood of Boston, Whittier Street Health Center provides comprehensive health services including primary care, behavioral health care, substance abuse services, dental care and eye care to over 25,000 patients. A trusted member of the community for 80 years, Whittier is here to provide the care that you and your family need to get healthy and stay healthy. We provide many services to help raise it out of poverty and into a place of good health. Having translators for 17 languages and utilizing clinical and social services to meet specific community needs through outreach, targeted programs and state of the art health care delivery helps us stay connected with the community.

UCHealth Pikes Peak Regional Hospital is a not-for-profit medical facility located in Woodland Park, Colorado, dedicated to enhancing individual and community health. The hospital aims to improve lives through a combination of innovative, academic-based medicine and a strong focus on community care. By offering evidence-based health care and wellness services, UCHealth strives to deliver comprehensive, high-quality medical care that meets the diverse needs of its patients. The hospital is part of a broader network that includes various clinics and outpatient services across northern Colorado, Nebraska, and Wyoming, emphasizing its commitment to serving a wide geographic area. With a mission centered on human connection and personal care, UCHealth Pikes Peak Regional Hospital plays a vital role in the health and well-being of the communities it serves.

Sankofa Community Development Corporation, established in 2008, is a nonprofit organization focused on revitalizing the Lower and Upper Ninth Ward communities of New Orleans. It aims to enhance urban living through various initiatives that promote healthy lifestyles, youth empowerment, and education. Key projects include the Sankofa Mobile Market, which provides access to fresh produce, the Sankofa HEAL Project, which emphasizes health education, and the Sankofa Learning Gardens and Farms Project, which fosters intergenerational learning and community engagement. Through these efforts, Sankofa Community Development seeks to create a safer, more stable, and sustainable environment for lower middle-class residents in the area.

Dr. Arenia C. Mallory Community Health Center (MCHC) is named to honor the memory of Dr. Arenia C. Mallory, well known educator and champion of human causes. She inspired young minds regardless of their race, economic or social status to “Walk in Dignity, Talk in Dignity, and Live in Dignity”.

Manna Ministries has a longstanding commitment to fiscal responsibility and is audited each year by an independent CPA firm. Our audits reveal that 96% of our funding goes directly to support our programs, while only 4% goes to administrative costs. Partnerships allows us to help more people lead healthier lives by providing them with the basic necessities of life such as food, shelter, and healthcare.

The Food Trust, a nonprofit founded in 1992, strives to make healthy food available to all. Working with neighborhoods, schools, grocers, farmers and policymakers, we've developed a comprehensive approach that combines nutrition education and greater availability of affordable, healthy food.

Christiana Care Health System, located in Wilmington, DE, is one of the largest healthcare providers in the mid-Atlantic region, serving Delaware and parts of Pennsylvania, Maryland, and New Jersey. As a not-for-profit teaching health system, it operates two hospitals with over 1,100 patient beds, alongside a comprehensive array of services including home health care, preventive medicine, and rehabilitation. The organization also maintains a robust network of primary care physicians and extensive outpatient services. Christiana Care is recognized for its excellence in various specialties, including cardiology, cancer treatment, orthopaedics, and women's health, as well as for its advanced Level-I trauma care and Level-3 neonatal intensive care capabilities.

Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California, with additional operations in Huntsville, Alabama, and Hyderabad, India. The company focuses on researching and developing investigational drugs for oncology, immunology, and virology, alongside a portfolio of partnered approved medicines. Its clinical pipeline includes notable candidates such as NKTR-181 for chronic low back pain, ONZEALD for advanced metastatic breast cancer, and Bempegaldesleukin, designed to enhance cancer-killing T cell activity. Nektar is also developing therapies for autoimmune diseases, including NKTR-358, and various other conditions like hemophilia A, opioid-induced constipation, and systemic lupus erythematosus. The company's strategy involves leveraging the immune system to combat cancer and restore immune balance in autoimmune disorders. Nektar has established collaboration agreements with several major pharmaceutical companies, enhancing its research capabilities and development efforts. Incorporated in 1990, Nektar Therapeutics continues to advance its innovative drug candidates through various stages of clinical trials.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

Omthera Pharmaceuticals, Inc. is a specialty pharmaceuticals company dedicated to the clinical development of new therapies for dyslipidemia, a condition characterized by elevated triglyceride levels that increases the risk of cardiovascular disease. The company is led by a team of experienced professionals in the field of lipid disorders, focusing on creating innovative treatments aimed at improving the health and quality of life for millions of affected patients. By concentrating on this specific area of healthcare, Omthera aims to address the unmet medical needs of individuals suffering from dyslipidemia and contribute to better management of cardiovascular risk.

Ardea Biosciences, based in San Diego, California, is a biotechnology company dedicated to developing small-molecule therapeutics aimed at treating serious diseases. The company’s primary focus is on RDEA594, a selective URAT1 transporter inhibitor currently in Phase 2 clinical development for the treatment of hyperuricemia and gout. Ardea's commitment to addressing significant health challenges positions it as a notable player in the biotechnology sector.

Guangdong BeiKang Pharmaceutical Company Ltd manufactures drugs which includes generic injectable antibiotics.

Novexel is a pharmaceutical company dedicated to the research and development of innovative anti-infective therapies for severe bacterial and fungal infections. With a robust portfolio of antibacterial and anti-fungal compounds, the company addresses the challenges posed by multi-resistant organisms. Novexel's expertise spans various scientific disciplines, including biology, medicinal chemistry, pharmacology, microbiology, and clinical development. This multidisciplinary approach positions the company at the forefront of discovering and developing new treatments for infectious diseases, aiming to provide effective solutions against microbial resistance.

MedImmune Ventures, Inc. is a venture capital firm that operates as a subsidiary of AstraZeneca, focusing on investments in biotechnology companies at various stages, from seed to late-stage financing. The firm targets both public and private enterprises engaged in developing small and large molecule therapeutics, vaccines, medical devices, diagnostics, and healthcare technologies. Its investment scope encompasses a range of therapeutic areas, including cardiology, gastroenterology, neuroscience, oncology, and infectious diseases, among others. MedImmune Ventures aims to support the discovery, development, and commercialization of innovative pharmaceutical products globally. Established in 2002, the firm is headquartered in Gaithersburg, Maryland, with an additional office in Mountain View, California, and typically invests around $7 million in its portfolio companies.

Arrow Therapeutics was founded in 1998 and is already making a significant contribution to anti-infective drug discovery. Microbial resistance to existing drugs is an ever increasing threat that is leading to serious unmet medical need and incurring a huge financial burden on society. Despite the huge challenges of this situation it also presents excellent opportunities to combine scientific research and business. As more and more big pharma groups concentrate their efforts on drug development, greater chances are open to smaller companies such as ours to show their excellence in research.

Cambridge Antibody Technology was a biotechnology company headquartered in Cambridge, England.

KuDOS Pharmaceuticals Ltd is a pharmaceutical research firm focused on the discovery and development of drugs targeting cancer treatment. The company utilizes the science of DNA damage sensing, signaling, and repair to create small molecule drugs that specifically inhibit the repair processes in cancer cells. This innovative approach aims to enhance the effectiveness of existing radiotherapy and chemotherapy, ultimately improving cancer management and outcomes for patients. By addressing critical medical needs in oncology, KuDOS Pharmaceuticals strives to contribute to advancements in cancer therapies.